Compare HRZN & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRZN | IRWD |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 295.1M | 741.8M |
| IPO Year | N/A | 2009 |
| Metric | HRZN | IRWD |
|---|---|---|
| Price | $4.24 | $3.67 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 5 |
| Target Price | ★ $6.80 | $4.94 |
| AVG Volume (30 Days) | 1.4M | ★ 2.8M |
| Earning Date | 01-01-0001 | 05-26-2026 |
| Dividend Yield | ★ 30.99% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | $19.99 | $57.95 |
| Revenue Next Year | $27.95 | $4.39 |
| P/E Ratio | ★ N/A | $24.50 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $4.00 | $0.55 |
| 52 Week High | $9.52 | $5.78 |
| Indicator | HRZN | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 17.25 | 42.86 |
| Support Level | N/A | $3.08 |
| Resistance Level | $6.81 | $3.93 |
| Average True Range (ATR) | 0.25 | 0.33 |
| MACD | -0.21 | -0.01 |
| Stochastic Oscillator | 9.57 | 44.41 |
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.